<html>
<head>PUBMED IDs for FSTL5</head>
<body bgcolor='#C5F0F2'><h1>FSTL5</h1><a href='https://pubmed.ncbi.nlm.nih.gov/21911727/'>FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.</a> February 15  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/25023989/'>A novel colorectal cancer risk locus at 4q32.2 identified from an international genome-wide association study.</a> March 17  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25023983/'>HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin.</a> December 15  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25023966/'>Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients.</a> May 15  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26045876/'>Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/Î²-catenin signaling in hepatocellular carcinoma.</a> March 10  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/27680702/'>XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.</a> September 30  2016<br></body></html>
